Neonatal General 1: Respiratory, BPD

Neonatal General 1: Respiratory, BPD

265 - ARG1 Expression as a Potential Biomarker for BPD Risk in Preterm Neonates

274 - Outcomes of infants receiving premedication during surfactant administration via Less Invasive Surfactant Administration and INtubation-SURfactant-Extubation

275 - Using urinary leukotriene E4 as an early predictor of severe histological chorioamnionitis exposure and the risk of developing chronic lung disease in extremely preterm infants

277 - Standardized Protocol for Caffeine Discontinuation in Extremely Preterm Infants: Impact on Practices, Cardiorespiratory Events, and Respiratory and Feeding Outcomes.

278 - Single center experience exploring NICU outcomes after initiating routine early use of hydrocortisone extremely low birthweight infants

279 - Little Stimulus: Unpacking Caffeine Use in Late Preterm Infants

266 - Metabolic Impact of Extended Continuous Positive Airway Pressure in Stable Preterm Infants: A Secondary Analysis of a Randomized Controlled Trial

267 - Sedative Use in Infants with Grade 3 Bronchopulmonary Dysplasia (BPD) and Associations with Neurodevelopmental Therapies

268 - Outcomes following Non-invasive Respiratory Support Failure in Moderately Preterm Infants

270 - Eye-tracking in neonatal intensive care: physicians' visual attention when evaluating the monitoring screen of a ventilator

271 - A single center study of predictors of early inhaled nitric oxide use in preterm infants

272 - Influence of flow rate change on CO2 levels during high flow nasal ventilation (HFNV) in preterm infants.

273 - Predicting Extubation Success in Premature Infants